Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients

Renal Failure

Volumn 33, Issue 9, 2011, Pages 892-898

  Kooshki, Akram ^a   Taleban, Forough Azam ^b   Tabibi, Hadi ^b   Hedayati, Mehdi ^b  

^a SABZEVAR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hematologic factors; Hemodialysis; Lipids; Lipoprotein (a); Marine omega 3 fatty acids

Indexed keywords

FISH OIL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; CHOLESTEROL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FATTY ACIDS, OMEGA-3; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053490909     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.605536     Document Type: Article

References (38)

1. Singh AK, Brenner BM. Dialysis in the treatment of renal failure. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrisons Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005:1663-1667
2. Jungers P, Nguyen Khoa T, Massy ZA, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: A multicentric study in the Ile de France district. Nephrol Dial Transplant. 1999;14:898-902 (Pubitemid 29155144)
3. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int. 1997;52(Suppl. 62):S53-S55 (Pubitemid 27489404)
4. Wanner C. Altered lipid metabolism and serum lipids in renal disease and renal failure. In: Kopple JD, Massry SG, eds. Kopple and Massrys Nutritional Management of Renal Disease. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:42-55
5. Loughrey CM, Young IS, McEneny J, et al. Oxidation of low-density lipoproteins in patients on regular hemodialysis. Atherosclerosis. 1994;110:185-193 (Pubitemid 24312438)
6. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson MC. Oxidation of low-density lipoproteins from patients with renal failure or renal transplants. Kidney Int. 1995;48:227-236
7. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis (abstr). Perit Dial Int. 1995;15:342-347
8. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol. 1998;82:34Q-46Q
9. Spinler SA, Cziraky MJ. Lipoprotein (a): Physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother. 1994;28:343-351 (Pubitemid 24105511)
10. Djurovic S, Berg K. Epidemiology of Lp (a) lipoprotein: Its role in atherosclerotic/thrombotic disease. Clin Genet. 1997;52: 281-292 (Pubitemid 28068616)
11. Dahlen GH, Stenlund H. Lp (a) lipoprotein is a major risk factor for cardiovascular disease: Pathogenic mechanisms and clinical significance. Clin Genet. 1997;52:272-280 (Pubitemid 28068615)
12. Ahmad S. Manual of Clinical Dialysis. 2nd ed. New York: Springer; 2009:199-200
13. Kuwahara M, Iimori S, Kuyama T, et al. Effect of anemia on cardiac disorders in pre-dialysis patients immediately before starting hemodialysis. Clin Exp Nephrol. 2011;15:121-125
14. Herrmann W, Biermann J, Kostner GM. Comparison of effects of n-3 to n-6 fatty acids on serum level of lipoprotein (a) in patients with coronary artery disease. Am J Cardiol. 1995;76:459-462
15. Svensson M, Schmidt EB, Jrgensen KA, Christensen JH. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic hemodialysis: A randomized placebo-controlled intervention study. Nephrol Dial Transplant. 2008;23:2918-2924
16. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: Double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13:184-190 (Pubitemid 34042026)
17. Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M. Effect of over-the-counter fish-oil administration on plasma Lp (a) levels in an end-stage renal disease population. J Ren Nutr. 2009;19:443-449
18. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, et al. Effect of n-3 fatty acids on nutritional status and inflammatory markers in hemodialysis patients. Nephrology (Carlton). 2007;12:331-336 (Pubitemid 47075407)
19. Vergili-Nelsen JM. Benefits of fish oil supplementation for hemodialysis patients. J Am Diet Assoc. 2003;103:1174-1177 (Pubitemid 39348744)
20. Vernaglione L, Cristofano C, Chimienti S. Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: A prospective cohort study. J Nephrol. 2008;21:99-105 (Pubitemid 351780578)
21. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol. 1992;2:1634-1639
22. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparation ultracentrifuge. Clin Chem. 1972;18:499-502
23. Daugirdas JT, Stone JCV. Physiologic principles and urea kinetic modeling. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:15-45
24. Bonanome A, Biasia F, De Luca M, et al. n-3 Fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects. Am J Clin Nutr. 1996;63:261-266
25. Fiedler R, Mall M, Wand C, Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr. 2005;15:253-256
26. Rolf N, Tenschert W, Lison AE. Results of a long-term administration of omega-3 fatty acids in hemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant. 1990;5:797-801 (Pubitemid 20373459)
27. Taziki O, Lessan-Pezeshki M, Akha O, Vasheghani F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007;18:571-576
28. Rylance PB, Gordge MP, Saynor R, Parsons V, Weston MJ. Fish oil modifies lipids and reduces platelet aggregability in hemodialysis patients. Nephron. 1986;43:196-202 (Pubitemid 16084319)
29. Hamazaki T, Nakazawa R, Tateno S, et al. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients. Kidney Int. 1984;26:81-84 (Pubitemid 14060592)
30. Azar R, Dequiedt F, Awada J, Dequiedt P, Tacquet A. Effects of fish oil rich in polyunsaturated fatty acids on hyperlipidemia of hemodialysis patients. Kidney Int Suppl. 1989;27: S239-S242 (Pubitemid 19285112)
31. Goren A, Drukker A, Stankiewicz H, Goldstein R. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics 1991;88:265-268
32. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr. 2000;10: 191-195
33. SvenssonM, Christensen JH, Slling J, Schmidt EB. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis. 2004;44: 77-83 (Pubitemid 38880930)
34. Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription. J Nutr. 2005;135:2503-2506 (Pubitemid 43156586)
35. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis related genes. Proc Natl Acad Sci USA. 1999;96:12737-12742 (Pubitemid 29513572)
36. Shimano H, Yahagi N, Amemiya-Kudo M, et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem. 1999;274:35832-35839 (Pubitemid 129512888)
37. Packard CJ, Shepherd J. Metabolic basis of the atherogenic lipoprotein phenotype. In: Gotto AM, Lenfant C, Catapano AL, Paoletti R, eds. Multiple Risk Factors in Cardiovascular Disease. Dordrecht: Kluwer Academic; 1995: 289-294
38. Lee RD, Nieman DC. Nutritional Assessment. 3rd ed. Boston, MA: McGraw-Hill; 2003:314-327